Crixivan

Crixivan is a brand name of indinavir, approved by the FDA in the following formulation(s):

CRIXIVAN (indinavir sulfate - capsule; oral)

• 
  Manufacturer: MERCK SHARP DOHME
  
  Approval date: March 13, 1996
  
  Strength(s): EQ 200MG BASE, EQ 400MG BASE ^[RLD]


• 
  Manufacturer: MERCK SHARP DOHME
  
  Approval date: April 19, 2000
  
  Strength(s): EQ 100MG BASE
  

Has a generic version of Crixivan been approved?

No. There is currently no therapeutically equivalent version of Crixivan available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Crixivan. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  HIV protease inhibitors useful for the treatment of AIDS
  Patent 5,413,999
  Issued: May 9, 1995
  Inventor(s): Vacca; Joseph P. & Dorsey; Bruce D. & Guare; James P. & Holloway; M. Katharine & Hungate; Randall W. & Levin; Rhonda B.
  Assignee(s): Merck & Co., Inc.
  Compounds of formula ##STR1## where R.sup.1 and R.sup.2 are independently hydrogen or optionally-substituted C.sub.1-4 alkyl or aryl, or R.sup.1 and R.sup.2 are joined together to form a monocyclic or bicyclic ring system, are HIV protease inhibitors. These compounds are useful in the treatment of infection by HIV and in the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of treating infection by HIV are also described.
  
  Patent expiration dates:
  
  
  • May 9, 2012
    
    ✓ 
    Patent use: INHIBITING HIV PROTEASE
  
  



• 
  Dry granulation formulation for an HIV protease inhibitor
  Patent 6,645,961
  Issued: November 11, 2003
  Inventor(s): Chung Y.; Lui & Drazen; Ostovic & Ashok V.; Katdare & Christine; Stelmach
  Assignee(s): Merck & Co., Inc.
  This invention relates to a dry granulation capsule formulation of the HIV protease inhibitor, indinavir sulfate, which is useful in the treatment of AIDS, ARC or HIV infection. Processes for making the oral formulation are also disclosed.
  
  Patent expiration dates:
  
  
  • March 4, 2018
    
    ✓ 
    Drug product
  
  



• 
  Combination therapy for HIV infection
  Patent 6,689,761
  Issued: February 10, 2004
  Inventor(s): Jeffrey A.; Chodakewitz & Emilio A.; Emini
  Assignee(s): Merck & Co., Inc.
  The combination of the HIV protease inhibitor Compound J, 3TC, and, optionally AZT, ddI, or ddC, is useful in the inhibition of HIV protease, the inhibition of HIV reverse transcriptase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
  
  Patent expiration dates:
  
  
  • February 10, 2021
    
    ✓ 
    Patent use: TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS
  
  

See also...

• Crixivan Consumer Information (Wolters Kluwer)
• Crixivan Consumer Information (Cerner Multum)
• Crixivan Advanced Consumer Information (Micromedex)
• Crixivan AHFS DI Monographs (ASHP)
• Indinavir Consumer Information (Wolters Kluwer)
• Indinavir Consumer Information (Cerner Multum)
• Indinavir Advanced Consumer Information (Micromedex)
• Indinavir Sulfate AHFS DI Monographs (ASHP)